BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 28, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Seres Therapeutics, Inc. (“Seres” or the “Company”) (NASDAQ: MCRB) securities between June 25, 2015 and July 29, 2016, inclusive (the “Class Period”). Seres investors have until November 28, 2016 to file a lead plaintiff motion.
According to the complaint filed in this lawsuit, throughout the Class Period defendants issued false and misleading statements to investors that Seres Therapeutics advertised and hyped its lead drug product candidate SER-109 as “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased Seres shares, you may move the Court no later than November 28, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.